Best in Biotech 26 Sep 2024
Europe’s rising biotech stars: 10 startups to watch in 2024
The European biotech industry is bustling with activity this year. Here’s a list of 10 European biotech companies likely to make a big splash.
Partnerships
- Latest Posts
In Depth 25 Sep 2024
How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market
Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ’90s.
In Depth 24 Sep 2024
New partnership model on the rise: how VCs are helping Pharma hunt for their next blockbuster
Discover how the recent Pfizer-Flagship alliance model sets a trend in pharma-VC partnerships, fostering innovation in drug development.
Best in Biotech 19 Sep 2024
Six immunology biotech companies revolutionizing immune treatments in 2024
Find out more about six immunology companies that have recently raised impressive funds in the biotech industry.
Expert Advice 13 Sep 2024
Stealth mode biotech startups: Everything you need to know
Discover all you need to know about stealth mode biotech startups, including what stealth mode is and its advantages and disadvantages.
News and Trends 10 Sep 2024
Long non-coding RNAs: what’s behind the growing “dark genome” buzz?
Recent deals have zoned in on drugs that target long non-coding RNAs and major moves are currently being made on the R&D front.
ADVERTISEMENT
ADVERTISEMENT
In Depth 3 Sep 2024
Adaptimmune: The long road toward finally bringing the first TCR-T cell therapy to the market
Find out about Adaptimmune’s long – and somewhat bumpy – road toward bringing the first TCR-T therapy to the market.
News and Trends 2 Sep 2024
Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration
Delve into the downturn AI is experiencing in biotech: Is the bubble bursting or is the market correcting the high expectations?
Best in Biotech 2 Aug 2024
Six epigenetics companies making strides in 2024
In this article, we take a look at six epigenetics companies that are significant as well as up-and-coming players in the industry.
In Depth 1 Aug 2024
CureVac: From a failed drug to a €1.45 billion deal
In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around.
In Depth 30 Jul 2024
Why is the immunology and inflammation market suddenly attracting a wave of investment?
Discover why the immunology and inflammation market has recently been attracting a major wave of investment.
More News! 23 Jul 2024
First AKT-targeting drug capivasertib to hit the market, could it open the door for more?
As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out!
ADVERTISEMENT
